http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
-
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
-
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Praxis Precision Medicines (PRAX) Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
-
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
-
Praxis Precision Medicines (PRAX) Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
-
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
-
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
-
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
-
Praxis Precision Medicines (PRAX) Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
-
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
-
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
-
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Praxis Precision Medicines (PRAX) Announces Positive Topline Results from PRAX-628 Phase 1 Study
-
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
-
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
-
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
-
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
-
Praxis Precision Medicines to Present at Upcoming Investor Conferences
-
Praxis Precision Medicines (PRAX) Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
-
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
-
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Praxis Precision Medicines (PRAX) and UCB Announce Epilepsy Research Collaboration
-
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
-
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
-
Praxis Precision Medicines (PRAX) to Initiate PRAX-562 Phase 2 EMBOLD Study in DEEs
-
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
-
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Praxis Precision Medicines to Present at Upcoming Investor Conferences
-
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
-
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing
-
Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Praxis Precision Medicines (PRAX) Provides Updates on Clinical Stage Pediatric Epilepsy Programs
-
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
-
Praxis Precision Medicines (PRAX) Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
-
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
-
Praxis Precision Medicines (PRAX) Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
-
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
-
Praxis Precision Medicines to Present at Upcoming Investor Conferences
-
Praxis Precision Medicines (PRAX) Reports Positive Topline Results from PRAX-944 Phase 2a Study
-
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
-
Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
-
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
-
Praxis Precision Medicines (PRAX) to Showcase Targeted Epilepsy Portfolio
-
Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
-
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022

